Plasma Ceramides (Ceramide Risk Score)
Ceramides are bioactive sphingolipids carried in the blood that accumulate in insulin-resistant, inflamed and lipotoxic tissues. Specific species — notably Cer(16:0), Cer(18:0) and Cer(24:1) — together with their ratios to Cer(24:0) are combined into a validated 'ceramide risk score' (reported on a 0-12 scale, e.g., the MI-Heart Ceramides / CERT score) that stratifies the risk of major adverse cardiovascular events independently of LDL cholesterol.
What It Measures
A weighted panel of plasma ceramide species and ratios expressed as a 0-12 risk score; higher scores reflect greater sphingolipid-driven cardiometabolic and atherosclerotic risk beyond what standard lipids capture.
Optimal vs. Lab Range
Target range for optimal health and longevity based on research.
Population-based reference range from standard labs.
Why It Matters
Plasma ceramides link lipotoxicity, insulin resistance and vascular inflammation — mechanisms central to arterial aging. Validation cohorts show the ceramide/phospholipid risk score (CERT1/CERT2) stratifies major adverse cardiovascular events and cardiovascular mortality independently of, and additively to, LDL-C, with roughly 1.4-1.7-fold higher event risk across the highest versus lowest categories; a 2026 dose-response meta-analysis found a consistent, graded increase in cardiovascular risk as the score rises. For a longevity-oriented practice, ceramides can help reclassify residual cardiometabolic risk in people whose conventional lipids look acceptable. The test is not FDA-approved and is best interpreted alongside ApoB, Lp(a) and inflammatory markers rather than in isolation.
When Low
Lower ceramide risk score (0-2): favorable sphingolipid profile, associated with lower near-term cardiovascular event risk.
When Optimal
A low score reflects minimal ceramide-driven cardiometabolic risk; interpret alongside ApoB, Lp(a) and hs-CRP.
When High
Higher score (7-12): elevated ceramide-associated risk of major adverse cardiovascular events and cardiovascular mortality; prompts intensified cardiometabolic risk management with your physician.
How to Optimize
Ceramide burden tracks with insulin resistance, excess adiposity and saturated-fat-driven lipotoxicity, so the measures that improve cardiometabolic health tend to lower it: weight and visceral-fat reduction, regular aerobic and resistance exercise, a predominantly whole-food dietary pattern richer in unsaturated fats and fiber, and treatment of dyslipidemia and insulin resistance where indicated. Some lipid-lowering therapies (e.g., statins) and omega-3 fatty acids have been reported to reduce ceramide levels. Retest on the same assay to track change. Decisions are individualized with your physician; this content is educational and not a substitute for medical advice.
Key Interventions & Linked Compounds
Moderate evidenceKey Interventions
Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.
Ordering Notes
Specimen
Plasma LC-MS/MS ceramide panel (e.g., MI-Heart Ceramides / CERT risk score)
Patient prep
No fasting required. Maintain usual diet and medications unless advised.
Recommended cadence
Periodic (e.g., with cardiovascular risk review); longitudinally on the same assay
Reporting unit
score (0-12)
Pre-analytic notes
Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.
Recommended Follow-Up Actions
- 1
Confirm the result is reliable
Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift Plasma Ceramides (Ceramide Risk Score).
- 2
Compare against optimal, not just lab range
Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.
- 3
Pair with related markers
Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.
- 4
Discuss interventions with a clinician
Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.
- 5
Re-test on a defined cadence
If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.
Testing Information
Recommended Frequency
Periodic (e.g., with cardiovascular risk review); longitudinally on the same assay
Fasting Requirement
No fasting required
Available Test Types
Quick Actions
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
